Clinical Medical Research Center for Women and Children Diseases, Key Laboratory of Birth Defect Prevention and Genetic Medicine of Shandong Health Commission, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, China.
Department of Obstetrics, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, China.
Front Immunol. 2023 Jul 6;14:1224892. doi: 10.3389/fimmu.2023.1224892. eCollection 2023.
Activator protein-1 (AP-1) is a transcription factor that consists of a diverse group of members including Jun, Fos, Maf, and ATF. AP-1 involves a number of processes such as proliferation, migration, and invasion in cells. Dysfunctional AP-1 activity is associated with cancer initiation, development, invasion, migration and drug resistance. Therefore, AP-1 is a potential target for cancer targeted therapy. Currently, some small molecule inhibitors targeting AP-1 have been developed and tested, showing some anticancer effects. However, AP-1 is complex and diverse in its structure and function, and different dimers may play different roles in different type of cancers. Therefore, more research is needed to reveal the specific mechanisms of AP-1 in cancer, and how to select appropriate inhibitors and treatment strategies. Ultimately, this review summarizes the potential of combination therapy for cancer.
激活蛋白-1(AP-1)是一种转录因子,由多种成员组成,包括 Jun、Fos、Maf 和 ATF。AP-1 涉及细胞中的许多过程,如增殖、迁移和侵袭。AP-1 功能障碍与癌症的发生、发展、侵袭、迁移和耐药性有关。因此,AP-1 是癌症靶向治疗的潜在靶点。目前,已经开发和测试了一些针对 AP-1 的小分子抑制剂,显示出一些抗癌作用。然而,AP-1 在结构和功能上复杂多样,不同的二聚体在不同类型的癌症中可能发挥不同的作用。因此,需要进一步研究来揭示 AP-1 在癌症中的具体机制,以及如何选择合适的抑制剂和治疗策略。最终,本文综述了联合治疗癌症的潜力。